Scleroderma News

OnabotulinumtoxinA offers short-term relief to patients suffering from scleroderma/systemic sclerosis-induced microstomia, according to a study.

Managing comorbidities is critical to minimizing deaths in patients with rheumatic and musculoskeletal diseases, according to data presented at EULAR 2023 Congress.

For diagnosing systemic sclerosis-related ILD, Krebs von den Lungen-6, surfactant protein-D and interleukin-8 in blood/bronchoalveolar lavage fluid samples were found to be “reliable biomarkers,” according to results published in Thorax.

A composite biomarker index could improve the risk stratification and diagnosis of interstitial lung disease in patients with systemic sclerosis, according to data published in Arthritis & Rheumatology.

Patients diagnosed with systemic sclerosis-related pulmonary hypertension in the last 10 years had better survival than those diagnosed prior, according to results published in American Journal of Respiratory and Critical Care Medicine.

A hypochromic red cells concentration of more than 2% is an independent predictor of mortality in patients with systemic sclerosis, according to data published in Arthritis Research & Therapy.

The use of proton pump inhibitors improves overall and progression-free survival in patients with systemic sclerosis-associated interstitial lung disease, according to data published in Rheumatology.

Rituximab was associated with significant improvements in both skin and lung parameters over long-term follow-up in a cohort of patients with systemic sclerosis, according to a study.

A fully automated analysis of nailfold images was able to distinguish patients with systemic sclerosis from those with normal capillaries at least as well as human experts, according to data published in Rheumatology.

Patients with systemic sclerosis who report more severe reflux symptoms demonstrate worse interstitial lung disease outcomes despite receiving standard therapy, according to data published in Arthritis Care & Research.